NALP2 antibody, C-term

GeneTex

NALP2 antibody, C-term

9

WB: 1-2microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Western Blot

Research Use Only

Polyclonal

0.50 mg/ml

Unconjugated

NLRP2

NLR family pyrin domain containing 2

CLR19.9; NACHT, leucine rich repeat and PYD containing 2; NACHT, LRR and PYD domains-containing protein 2; NALP2; NBS1; nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 2; nucleotide-binding site protein 1; PAN1; PYPAF2; PYRIN domain and NACHT domain-containing protein 1; PYRIN-containing APAF1-like protein 2

Goat

IgG

NACHT, LRR and PYD domains-containing protein 2

This gene is a member of the nucleotide-binding and leucine-rich repeat receptor (NLR) family, and is predicted to contain an N-terminal pyrin effector domain (PYD), a centrally-located nucleotide-binding and oligomerization domain (NACHT) and C-terminal leucine-rich repeats (LRR). Members of this gene family are thought to be important regulators of immune responses. This gene product interacts with components of the IkB kinase (IKK) complex, and can regulate both caspase-1 and NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity. The pyrin domain is necessary and sufficient for suppression of NF-kB activity. An allelic variant (rs147585490) has been found that is incapable of blocking the transcriptional activity of NF-kB. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2016]

Human

-20°C or -80°C,2°C to 8°C

12352203